Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP1 | P22413 | 7/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
| ▸ | KDR | P35968 | 3/20 | 0.55 |
| ▸ | PDGFRB | P09619 | 7/20 | 0.54 |
| ▸ | ACHE | P22303 | 1/20 | 0.53 |
| ▸ | BACE1 | P56817 | 1/20 | 0.53 |
| ▸ | PDGFRA | P16234 | 3/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11484522 | 0.89 | ENPP1 (0.62) | ENPP1MAPK1KDRPDGFRBACHE | |
| SCHEMBL24391608 | 0.83 | ENPP1 (0.67) | ENPP1MAPK1PDGFRBACHEBACE1 | |
| SCHEMBL11494695 | 0.80 | ENPP1 (0.59) | ENPP1MAPK1PDGFRBACHEBACE1 | |
| SCHEMBL4966150 | 0.79 | PDGFRB (0.70) | ENPP1KDRPDGFRBACHEBACE1 | |
| SCHEMBL4965169 | 0.79 | ENPP1 (0.61) | ENPP1MAPK1PDGFRBACHEBACE1 | |
| SCHEMBL4969629 | 0.78 | PDGFRA (0.60) | ENPP1KDRPDGFRBACHEBACE1 | |
| SCHEMBL4966896 | 0.78 | PDGFRA (0.57) | ENPP1KDRPDGFRBPDGFRA | |
| SCHEMBL4966832 | 0.78 | PDGFRB (0.71) | ENPP1KDRPDGFRBPDGFRA | |
| SCHEMBL3072691 | 0.77 | ENPP1 (0.57) | ENPP1MAPK1PDGFRBACHEBACE1 | |
| SCHEMBL20814063 | 0.77 | ENPP1 (0.68) | ENPP1MAPK1PDGFRBACHEBACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 139 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3621593-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING CARDIOVASCULAR DISEASES | Cardix Therapeutics LLC (US) | 2020-03-18 | — | — | EP | claimed |
| WO-2019194866-A1 | DEUTERATED PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING CARDIOVASCULAR DISEASES | Cardix Therapeutics LLC (US) | 2019-10-10 | — | — | WO | claimed |
| US-20190231786-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING CARDIOVASCULAR DISEASES | CARDIX Therapeutics, LLC | 2019-08-01 | — | — | US | claimed |
| CN-109890366-A | Combination medicine for treating cardiovascular diseases and preparation and use methods thereof | 美进医药公司 | 2019-06-14 | — | — | CN | claimed |
| US-20190070184-A1 | DEUTERATED PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING CARDIOVASCULAR DISEASES | Cardix Therapeutics LLC (US) | 2019-03-07 | — | — | US | claimed |
| WO-2018208723-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING CARDIOVASCULAR DISEASES | Cardix Therapeutics LLC (US) | 2018-11-15 | — | — | WO | claimed |
| US-20180325907-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING CARDIOVASCULAR DISEASES | CARDIX Therapeutics, LLC | 2018-11-15 | — | — | US | claimed |
| CN-101330905-A | Freeze-drying process and products obtained thereby | SCIDOSE LLC (US) | 2008-12-24 | — | — | CN | claimed |
| US-6297243-B1 | TREATING OSTEOPENIA THAT ACCOMPANIES THE MENOPAUSE | NOVO NORDISK A/S (DK) | 2001-10-02 | — | — | US | claimed |
| JP-2001500865-A | — | — | 2001-01-23 | — | — | JP | claimed |
| EP-0961616-A4 | NON-HORMONAL METHOD OF CONTRACEPTION | TRUSTEES OF BOARD OF (US) | 2000-11-22 | — | — | EP | claimed |
| US-6110471-A | ADMINISTERING PHOSPHODIESTERASE FOR INHIBITION OF THE CYCLES | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2000-08-29 | — | — | US | claimed |
| EP-1028690-A2 | LUTEINISING HORMONE ANTAGONISTS USEFUL FOR TREATMENT OF ESTROGEN DEFICIENCIES, OR AS A CONTRACEPTIVE | NOVO NORDISK A/S (DK) | 2000-08-23 | — | — | EP | claimed |
| EP-0961616-A1 | NON-HORMONAL METHOD OF CONTRACEPTION | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 1999-12-08 | — | — | EP | claimed |
| WO-1999020223-A2 | LUTEINISING HORMONE ANTAGONISTS USEFUL FOR TREATMENT OF ESTROGEN DEFICIENCIES, OR AS A CONTRACEPTIVE | NOVO NORDISK A/S (DK) | 1999-04-29 | — | — | WO | claimed |
| WO-1998010765-A1 | NON-HORMONAL METHOD OF CONTRACEPTION | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 1998-03-19 | — | — | WO | claimed |
| EP-4109850-B1 | CONTROL PLANE BASED CONFIGURATION FOR TIME SENSITIVE NETWORKING | TOYOTA MOTOR CO LTD (JP) | 2026-05-20 | — | — | EP | disclosed |
| US-12587440-B2 | Stateful management of network device configurations | CISCO TECHNOLOGY, INC. (US) | 2026-03-24 | — | — | US | disclosed |
| US-4489075-A | Cyclic sulfonamidoalkyl substituted 4-piperidinoquinazoline cardiac stimulants | PFIZER INC. (US) | 1984-12-18 | — | — | US | disclosed |
| EP-0094766-A2 | Quinazoline cardiac stimulants | Pfizer Limited (GB) | 1983-11-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12587440-B2 | Stateful management of network device configurations | LGMN, TRRAP, CTCF | ENPP1 4419/4885MAPK1 2938/4885KDR 4316/4885 |
| US-20190070184-A1 | DEUTERATED PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING CARDIOVASCULAR DISEASES | ADRB2, ADRA2C, ADRB1 | ENPP1 1218/4885MAPK1 3085/4885KDR 1096/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.